The complement system plays an important role in the induction of inflammation. In this study we demonstrate that the initiation complexes of the lectin pathway, consisting of mannose-binding lectin (MBL) and associated serine proteases (MASPs) elicit Ca 2+ signaling in cultured endothelial cells (HUVECs). This is in agreement with our previous results
Introduction
The complement system is a major effector arm of innate immunity. Its main functions are labeling and eliminating invading pathogens and altered self structures, triggering inflammation, and modulating the adaptive immune response (Ricklin et al., 2010) . This network of about 40 proteins includes recognition molecules, serine proteases, thioester containing molecules, cell-surface-receptors and regulators. The danger signals presented by invading pathogens (PAMP: pathogen associated molecular pattern) or by altered host cells (DAMP: damage or danger associated molecular pattern) are recognized by pattern recognition molecules. The lectin pathway of the complement system has at least five different pattern recognition molecules: mannose-binding lectin (MBL), H-, L-and M-ficolin (also named ficolin-3, -2, -1, respectively) (Thiel, 2007) and collectin-11 (also named collectin kidney 1) (Hansen et al., 2010) . These molecules may recognize specific patterns of carbohydrate arrays on the surface of microorganisms, hence the name "lectin pathway". The recognition event is converted into an enzymatic signal by serine proteases that are associated with the pattern recognition molecules. MBL and ficolins associate with three serine proteases: MASP (MBL-associated serine protease)-1, -2 and -3 (Matsushita and Fujita, 1992; Thiel et al., 1997; Dahl et al., 2001) , and with two non-catalytic proteins MAp44 (Degn et al., 2009; Skjoedt et al., 2010) and MAp19 (Stover et al., 1999; Takahashi et al., 1999) . The composition and the stoichiometry of the MBL-MASPs and ficolin-MASPs complexes are not known but it seems likely that a number of different complexes exist in the plasma. When the pattern recognition molecules bind to the target structure, the zymogen serine proteases become activated. An Arg-Ile bond is cleaved in the activation loop, which results in conformational change in the serine protease domain. Recently, we have shown that MASP-1, the most abundant protease component of the lectin pathway, controls lectin pathway activation Héja et al., 2012a; 2012b; Kocsis et al., 2010; Megyeri et al., 2013) . MASP-1 autoactivates and cleaves zymogen MASP-2, which then cleaves C4 and C2 components (Kidmose et al., 2012) . The resulting C3 convertase (C4b2a) is responsible for maintenance and amplification of the complement cascade.
One of the most important functions of the complement cascade is to trigger inflammation. The split products released during complement activation (e.g. anaphylatoxins:
C3a, C5a) activates leukocytes and endothelial cells through G protein-coupled receptors.
Recently, we have discovered a new function of the complement system that may contribute to the pro-inflammatory effect of complement activation. MASP-1, like thrombin, is capable of activating endothelial cells directly through cleavage of protease activated receptor 4 (PAR4) (Megyeri et al., 2009 earlier that MBL binds to endothelial cells (Oroszlán et al., 2007) , and we cannot exclude the possibility that this binding modulates the effect of MASP-1 on the cells besides changing the local concentration of MASP-1 on the surface of the cells. It is therefore important to examine whether native MASPs in complexes with MBL are able to activate endothelial cells.
In the present study we analyzed the effect of MBL-MASPs complexes on endothelial cells. We isolated MBL-MASPs complexes from human plasma and studied their ability to stimulate endothelial cells. We also wanted to show unambiguously that proteolytically inactive MASP-1 and the N-terminal non-catalytic regions of MASP-1/3 and MASP-2 are unable to activate cells. Moreover, we asked whether zymogen MASP-1 is able to activate endothelial cells similarly to activated MASP-1. Finally, we also examined whether the catalytic activity of the third protease component of the lectin pathway, MASP-3, exerts any effect on HUVECs.
Materials and Methods

Materials
CNBr-activated Sepharose 4B was from GE Healthcare. Coupling of mannan to CNBr-activated resin was performed according to the manufacturer's instructions. All the other reagents were purchased from Sigma-Aldrich, unless otherwise stated. Lyophilized plasma C1 inhibitor (C1-inh, Berinert P) was from ZLB Behring, and it was further purified by cation-exchange chromatography (Source 15S column; GE Healthcare) and gel filtration (Sephadex 75 HiLoad 16/60; GE Healthcare).
Recombinant MASP fragments
DNA constructs of recombinant human MASP-1, and -2 catalytic fragments encoding the CCP1-CCP2-SP region (rMASPcf) were used for expression in E. coli as described (Ambrus et al., 2003) . rMASP-2cf was prepared according to Gál et al. (Gál et al., 2005) . The R448Q and S646A (precursor numbering) mutants of rMASP-1cf were made according to Megyeri et al. (Megyeri et al., 2013) . Wild-type (wt) rMASP-1cf was produced as described by Dobó et al. (Dobó et al., 2008 (Dobó et al., , 2009 ), but in the absence of benzamidine. The two-step purification procedure was performed in a single day in order to minimize degradation.
The R448Q and the S646A variants of rMASP-1cf were prepared the same way as the wt enzyme, however in these cases the procedure yields the proenzymic (one-chain) form (Megyeri et al., 2013) . The S646A mutant of rMASP-1cf at 100 g/mL was cleaved by rMASP-2 catalytic fragment (2.5 g/mL) by overnight incubation at room temperature to bring the enzyme into the two-chain form. After cleavage, the S646A mutant was further purified by repeating the anion exchange chromatographic step on a Source 30Q column to remove rMASP-2cf. We used rMASP-2cf to cleave rMASP-1cf S646A since the two can be separated due to their distinct chromatographic behavior. The procedure yielded an enzyme, which was in the active conformation, but due to the absence of the catalytic serine it had no catalytic activity. Since MASP-2 does not activate endothelial cells (Megyeri et al., 2009) traces of MASP-2 (if any) would not interfere with the cell activation assay.
Wild type proenzymic rMASP-3cf was produced as previously described (Megyeri et al., 2013) . Purified rMASP-3cf (400 g/mL) was activated by cleavage with rMASP-1cf (25 g/mL) at 37 o C for 3 hours. In the next step rMASP-1cf were removed from the samples by cation exchange chromatography on a SP Sepharose High Performance (GE Healthcare)
column. The N-terminal fragments (CUB1-EGF-CUB2) of MASP-1 and MASP-2 were prepared as described by Paréj et al. (2014) .
Purification of MBL-MASPs complexes
MBL-MASPs complexes were purified by a modified method described by Matsushita et al (Matsushita et al., 2000b) . Briefly: plasma samples were clotted by the addition 25 mM CaCl 2 , 0.1 mg/ml Pefabloc, and 2% mannitol. After washing the resin with the same buffer, the MBL-MASPs complexes were eluted from the mannan-beads using the above buffer containing 0.3 M mannose. The MBL and MASP-1 concentrations in the eluted samples were determined by sandwich-type immune-assays (see below) as previously described 2002) .
To increase the yield of the purified MBL-MASPs complexes we modified the protocol by adding 10 µg/ml recombinant MBL to the serum samples before incubation with mannan-Sepharose 4B resin. After elution, the fractions were checked by TRIFMA and the appropriate fractions were pooled and concentrated on a spin concentrator and dialyzed against Hank's Balanced Salt Solution (HBSS) and kept at -80 o C until use on endothelial cells.
C1-inhibitor treatment
In some control experiments the activity of the plasma derived and recombinant MASP-1 was blocked by C1-inhibitor. The proteases were incubated with C1-inhibitor in a 1:1 molar ratio at 37 o C for 20 min before adding to the HUVECs.
Western blot analysis of purified MBL-MASP complexes
The Western blot analysis of the purified complexes was performed using the antibodies and the protocol described in detail in Degn et al. (Degn et al., 2010) . The rabbit antiserum towards MASP-1, Rabbit64, was raised against the 19 amino acid located on the Cterminus of MASP-1, and thus recognizes the serine protease domain of MASP-1, also called the B chain. Images were taken by CCD camera (LAS-3000, Fuji) and analyzed by the software supplied with the camera.
Assay of the lectin pathway components in the purified complexes
Concentration measurements of MASP-1 , MASP-3 and MAp44 (Degn et al., 2010) , MASP-2 (Møller-Kristensen et al., 2003) , MAp19 (Degn et al., 2011) and MBL (Thiel et al., 2002) in the purified complexes were carried out, as described previously.
All assays are based on sandwich-type immunoassays performed in microtiter wells with the use of biotin-labeled detecting Abs followed by europium-labeled streptavidin. The amount of europium bound in the wells is subsequently measured by time-resolved fluorescence, and this assay type is therefore referred to as a time-resolved immunofluorimetric assay (TRIFMA).
Preparation and culture of HUVECs and measurement of intracellular Ca 2+ signaling by fluorescence microscopy
The preparation and culture of endothelial cells, and the Ca 2+ -mobilization measurements were performed as described previously (Megyeri et al., 2009) . Briefly, HUVECs were cultured in 96-well plates for 1 day then loaded with Fluo-4-AM (2 µM).
Three photos were taken on an Olympus XM-10 camera as a base-line then the activator was added to the cells and the response was measured for 2 minutes. The maximum fluorescence intensity and the base-line fluorescence intensity were calculated, and the differences were compared to those of positive controls.
Statistical analysis
Data were compared using one-way ANOVA with Tukey's post-test and Student's ttest (GraphPad Prism 4.02 software, GraphPad, http://www.graphpad.com/). A p-value less than 0.05 was considered significant. Data are presented as means ± SEM.
Results
Purification of MBL-MASPs complexes form human plasma
To assess whether MBL-MASPs complexes can stimulate endothelial cells, we purified MBL-MASPs complexes from human plasma according to the original protocol of Matsushita et al. (Matsushita et al., 2000a) and measured the quantity of the yielded MBL and MASP-1 in the different fractions (data not shown). We found that MASP-1 co-eluted from the affinity column with MBL and the amount of MBL was proportional to the MASP-1 concentration. Unfortunately, this protocol was not able to yield sufficient amount of MASP-1 for testing endothelial cell activation. In order to increase the yield of MBL-bound MASP-1, we added recombinant MBL (10 µg/ml) to the serum samples before incubation with the mannan-conjugated Sepharose 4B resin. While the original protocol yielded 8 µg MASP-1 from 100 ml serum, the modified one allowed us to isolate 160 µg MASP-1 from the same volume of serum. Apparently, the addition of recombinant MBL shifted the equilibrium in such a way that the amount of MBL-MASPs complexes increased considerably at the expense of the ficolin-MASPs complexes. The purified complex was characterized by Western blot analysis after fractionation in reducing conditions and developing the membrane with rabbit antisera (Rabbit 64) towards MASP-1 that recognizes the MASP-1 B chain (Degn et al., 2010) . It is known that MASP-1 is readily activated and we also find here that zymogen MASP-1 is autoactivated after the purification and dialysis against the HBSS buffer and subsequent concentration of the samples (Fig. 1 ).
On figure 1 we have marked the position of non-cleaved MASP-1 (MASP-1 zymogen) and the position of the protease domain, i.e. the B-chain (separated from the A chain since the SDS-PAGE was performed in reducing conditions), as well as a band representing a further degradation product, i.e. B´ chain. On the figure we have also marked the covalent complex that is formed between activated MASP-1 and C1-inhibitor. It can be seen on figure 1 that gradually more and more MASP-1 is activated during the dialysis and concentration steps.
We also determined the concentration of the different effector molecules in the purified and concentrated samples, and compared these values to the average concentrations measured in the starting sera (Table 1) shows a 10-fold enrichment compared to the reference value.
MBL-MASPs complexes trigger Ca 2+ -signaling in endothelial cells
After purification of the MBL-MASPs complexes from human plasma we applied them to HUVECs and measured the Ca 2+ signals by fluorescent microscopy. MBL-MASPs complexes containing 2 µM MASP-1 triggered intracellular Ca 2+ increase in endothelial cells in a similar way to histamine (50 µM), which was used as a positive control ( Fig. 2A) . The kinetics of the MBL-MASPs-induced intracellular Ca 2+ release is similar to what we have measured previously using recombinant MASP-1 catalytic fragment (rMASP-1cf) containing the serine protease domain and the two complement control protein modules (Megyeri et al., 2009 ). The MBL-MASPs-induced Ca 2+ signal was dose dependent correlating with the MASP-1 content of the MBL-MASPs complexes (Fig. 2B) . rMBL in the same concentration as found in the purified MBL-MASPs complexes (32 µM) did not induce Ca 2+ signals (Fig.   3 ). If we pre-incubated the MBL-MASPs complexes with C1 inhibitor (C1-inh) in a 1:1 molar ratio the effect was inhibited (Fig. 3) .
Proteolytically inactive forms MASP-1 catalytic fragments do not activate endothelial cells
MASP-1 circulates in zymogen (proenzyme) form in the blood and it autoactivates only when the recognition molecule of the complex binds to target surface. We wanted to investigate whether MASP-1, and consequently the lectin pathway of complement, needs to be activated for triggering pro-inflammatory signals on endothelial cells. Previously, we created a stable proenzyme rMASP-1cf (R448Q) molecule by mutating the activation loop arginine to glutamine (Megyeri et al., 2013) . This mutant cannot be cleaved by trypsin-like serine proteases and retains its one-chain proenzyme form. We added the zymogen rMASP1cf R448Q mutant to the cells and measured the Ca 2+ signaling by fluorescent microscopy.
The zymogen R448Q mutant did not trigger Ca 2+ signals on HUVECs even at high concentration (2 µM) (Fig. 4A,B) , whereas the wild type rMASP-1cf as well as the MBLMASPs complexes activated the cells. This indicates that MASP-1 needs to be in active form to be able to induce pro-inflammatory signaling on endothelial cells.
As we have shown here using the MBL-MASPs complex and previously using the rMASP-1cf catalytic fragment (Megyeri et al., 2009) , the effect of MASP-1 could be inhibited by pre-incubation with equimolar amount of C1-inh (Fig. 3 ). This suggested, but did not incontrovertibly prove that the proteolytic activity of MASP-1 is responsible for PAR4
cleavage on endothelial cell surface. C1-inh forms a covalent complex with MASP-1 (Davis et al., 2008; Paréj et al., 2013) , possibly distorting its structure and preventing the access of MASP-1 to their receptors. In order to unambiguously prove that the proteolytic activity of MASP-1 is responsible for cell activation, we created a proteolytically inactive form of MASP-1 catalytic fragment, which has the conformation of the active protease. We mutated the catalytic serine residue to alanine (S646A) as previously described (Megyeri et al., 2013) and cleaved the R 448 -Ile 449 activation bond by MASP-2. Thus, we produced a proteolytically inactive two-chain form of rMASP-1cf. After administration of the inactive rMASP-1cf
(S646A) to HUVECs we could not detect any Ca 2+ -signals by fluorescent microscopy ( Fig.   4A,B) .
The N-terminal region of MASP-1 and MASP-2 do not activate endothelial cells
The MBL-MASPs complexes, besides the full-length serine proteases, contain the non-catalytic splice products of the MASP1 and MASP2 genes, MAp44 and MAp19, respectively. These molecules consist of the N-terminal interacting domains of the MASPs. In order to prove that the N-terminal non-catalytic region of MASP-1 and MASP-2 do not activate endothelial cells, we incubated HUVECs with recombinant fragments containing the three N-terminal domains (CUB1-EGF-CUB2) of the proteases. These proteins showed no detectable effect on the cells (Fig. 3) , even at high concentration, corroborating that the proteolytic activity of MASP-1 is the key factor for cell activation, and other domains of the MASPs do not interact with receptors. These experiments also very strongly suggest that the two non-catalytic MBL-associated proteins, MAp19 and MAp44 do not contribute to the direct cell-activating ability of the complexes.
MASP-3 does not activate endothelial cells
Besides MASP-1 the MBL-MASPs complexes contain two other proteases: MASP-2 and MASP-3. We have previously shown that MASP-2 do not activate endothelial cells (Megyeri et al., 2009) . In this study we also wanted to examine whether the proteolytic activity of MASP-3, the second most abundant protease of the lectin pathway, contributes to the pro-inflammatory effect. We produced the recombinant catalytic fragment (CCP1-CCP2-SP) of MASP-3 (Megyeri et al., 2013) . MASP-3, unlike MASP-1 and MASP-2, does not autoactivate but it can be activated by MASP-1 cleavage. We cleaved the rMASP-3cf by rMASP-1cf and carefully removed the traces of rMASP-1cf form the active rMASP-3cf
sample. Endothelial cells were treated with activated rMASP-3cf and the Ca 2+ response was assessed. rMASP-3cf did not activate the HUVECs even at high concentration implicating that MASP-1 is the exclusive activator of the endothelial cells among the components of the MBL-MASPs complexes (Fig 3) .
Discussion
The lectin pathway of the complement system is an important effector arm of the innate immunity. After the pattern recognition molecules bind to the activator structures, the Recently it has been shown that MASP-1 also activates hepatic stellate cells (Saeed et al., 2013) . Although the mechanism is not clarified yet, it seems likely that MASP-1 cleaves protease activated receptor on the hepatic cells. This phenomenon shows that the cellactivating ability of MASP-1 is not confined to endothelial cells.
Another recent paper reports that MBL induces cell death of proximal tubular epithelial cells (PTEC) during renal ischemia/reperfusion injury (IRI) without complement activation; i.e. no C3 deposition or C5b-9 complex formation was necessary for the cytotoxic effect (van der Pol et al., 2012) . Although it was shown that MBL itself mediates cell death in PTEC cell culture, we cannot rule out the contribution of MASP-1 in the in vivo situation.
During IRI, MBL in the serum specifically binds to the stressed cells, which is followed by the activation of associated MASP-1. The proteolytic action of MASP-1 on the PTE cells might contribute to the toxic effect immediately, preceding C3 and C5 convertase formation.
This hypothesis might be checked in the future using MASP-1 specific inhibitors (Heja et al., 2012a ).
The effect of the MBL-MASPs complexes and that of rMASP-1cf can be abolished by C1-inh treatment. C1-inh is a serpin (serine protease inhibitor) that makes a covalent complex with the protease molecule, distorting its structure and preventing cleavage of further substrate molecules (Beinrohr et al., 2007) . We wanted to unambiguously exclude the possibility that the C1-inh mediated inhibition of the cell activating ability of MASP-1 is due to steric reasons; i.e. the complex formation with C1-inh simply prevents the binding the protease to the receptor and the lack of proteolytic activity plays no role in the inhibition.
Neither the stable zymogen one-chain mutant form of rMASP-1cf (R448Q) nor the activation loop cleaved but proteolytically inactive mutant (S646A) was able to exert any effect on . We supplemented the serum with 400 nM recombinant MBL which dramatically increased the yield of the associated proteins. Hence it is obvious that the MASPs and MAps can migrate between the recognition molecules and the system is in dynamic equilibrium. This equilibrium can be shifted by adding empty (uncomplexed) recognition molecules to the serum. It is interesting that although complete dissociation of the MBL-MASPs complexes can be achieved only in the presence of EDTA and high ionic strength (Thiel et al., 2000) , the associated proteases can readily migrate between the recognition molecules in the normal human plasma. It may also be possible that when an empty pattern recognition molecule binds to the activator surface it can recruit
MASPs form the serum to generate the initiation complex. Another alternative would be that in serum there is a surplus of MASPs that are not bound to pattern recognition molecules but may be bound if we add a much higher concentration of MBL.
In conclusion, we showed that MBL-MASPs complexes are able to activate endothelial cells via the proteolytic activity of MASP-1. Our results strengthen the view that MASP-1 plays a central role in the early innate immune response. After autoactivation it initiates the lectin pathway by activating MASP-2 and MASP-3, and it also has proinflammatory activity by cleaving other substrates, such as protease activated receptor, high molecular weight kininogen (Dobó et al., 2011) and fibrinogen (Gulla et al., 2009; Hess et al., 2012) . In this way MASP-1 initiates a multi-faceted response against the possibly dangerous particles recognized by the pattern recognition molecules. 
